Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | STAT6 | P42226 | 1/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | HTR7 | P34969 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | GFER | P55789 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422527 | 0.90 | CYP1A2 (0.75) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL30422981 | 0.90 | CYP1A2 (0.75) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL5837665 | 0.89 | CYP1A2 (1.00) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL11339285 | 0.87 | CYP1A2 (0.71) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL11299646 | 0.87 | CYP1A2 (0.71) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL2208304 | 0.87 | CYP1A2 (0.71) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL30423175 | 0.87 | CYP1A2 (0.71) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL19614388 | 0.87 | CYP1A2 (0.71) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL15501213 | 0.87 | CYP1A2 (0.71) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL11590344 | 0.87 | CYP1A2 (0.71) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303311-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | Neurochem, Inc. (CA) | 2003-04-23 | — | — | EP | claimed |
| WO-2002007781-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | NEUROCHEM INC. (CA) | 2002-01-31 | — | — | WO | claimed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| CN-116926578-A | Method for synthesizing heteroaryl thiophenol | 新疆大学 | 2023-10-24 | — | — | CN | disclosed |
| WO-2023146973-A1 | SYNTHESIS OF A KIF18A INHIBITOR | AMGEN INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20210228550-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2021-07-29 | — | — | US | disclosed |
| US-10945996-B2 | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190209531-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2019-07-11 | — | — | US | disclosed |
| US-10172905-B1 | Treatment of protein degradation disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| US-8173688-B2 | Thiazole compounds, and compositions and methods using same | NEXMED HOLDINGS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20120010204-A1 | Phthalazinone Derivatives | MAYBRIDGE LIMITED | 2012-01-12 | — | — | US | disclosed |
| US-20090311343-A1 | Thiazole Compounds, and Compositions and Methods Using Same | NEXMED HOLDINGS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1995240-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-4245033-A | AN ORGANIC SILVER SALT, A HALIDE AND A SULFUR COMPOUND EXPOSED TO FORM A SILVER IMAGE OF HIGH CONTRAST AND STABILITY | CANON KABUSHIKI KAISHA (JP) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10945996-B2 | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis | CASP3, SI, PYCARD | CYP1A2 3963/4885CYP2D6 4825/4885CYP2C19 2607/4885 |
| US-10172905-B1 | Treatment of protein degradation disorders | HDAC6, HDAC5, AADAC | CYP1A2 4554/4885CYP2D6 4350/4885CYP2C19 4726/4885 |
| US-20120010204-A1 | Phthalazinone Derivatives | NR0B1, NR0B2, NR2E1 | CYP1A2 542/4885CYP2D6 1407/4885CYP2C19 912/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | CYP1A2 4381/4885CYP2D6 3250/4885CYP2C19 2378/4885 |
| US-20190209531-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | CYP1A2 3963/4885CYP2D6 4825/4885CYP2C19 2607/4885 |
| US-20210228550-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | CYP1A2 3963/4885CYP2D6 4825/4885CYP2C19 2607/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | CYP1A2 2147/4885CYP2D6 1529/4885CYP2C19 281/4885 |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | CYP1A2 542/4885CYP2D6 1407/4885CYP2C19 912/4885 |
| US-20090311343-A1 | Thiazole Compounds, and Compositions and Methods Using Same | RCC2, PKD1, REN | CYP1A2 2196/4885CYP2D6 1102/4885CYP2C19 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.